Results

1–10 of 21 results for Neovascular Age‐related Macular Degeneration

Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment ofGeographic Atrophy and Neovascular AMD
Nimesh A. Patel, MD
Annual Meeting Talks
2025
Expert Panel:PDS
Robert A. Mittra, MD, FASRS
Dante Joseph Pieramici, MD
Aleksandra V. Rachitskaya, MD, FASRS
Margaret A. Chang, MD, MS
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2024
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
AI-Based Spatiotemporal Observations of Retinal Fluid Dynamics Using the Notal Vision Home OCT
Anat Loewenstein, MD
Annual Meeting Talks
2022
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021